A possible pharmacological chaperone for congenital erythropoietic porphyria

The Chassys platform has been successfully applied for the identification of a series of putative pharmacological chaperones for the treatment of congenital erythropoietic porphyria. One of them is currently being validated, with most promising results. See also “Una molécula ‘carabina’ para aplacar la porfiria congénita”.

2021-01-03T12:40:29+01:00March 6th, 2017|News|

Atlas Molecular Pharma will be attending BioSpain 2016 in Bilbao, September 28th – 30th

Join us at BioSpain 2016 in Bilbao, September 28th – 30th. If you want to find out more about what we do and are a potential Investor or Partner, please contact us through the BioSpain Partnering platform or by email to noccleston@atlasmolecularpharma.com

2021-01-03T12:40:25+01:00September 12th, 2016|News|

CIC bioGUNE, CRB Inverbío, Kereon Partners and private investors create Atlas Molecular Pharma to discover new drugs for the treatment of Rare and Ultra-Rare diseases

The new company, Atlas Molecular Pharma, will further develop its proprietary technology to act as a “drug discovery engine” for the discovery and development of drugs called pharmacological chaperones, which act by restoring defective protein activity – this is a common pathological mechanism which Atlas will target, and is present in around 80% of the [...]

2021-01-03T12:40:18+01:00September 12th, 2016|News|
Go to Top